A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Trial Profile

A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 08 Aug 2016 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
    • 28 Apr 2016 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top